Visit Our Blog
  • FDNA TELEHEALTH
  • Products
    • Face2Gene Labs
    • Face2Gene Clinic
  • About FDNA
  • News & Press
    • In The News
    • Press Releases
  • Contact
  • FDNA Insights

FDNA Insights

Categories
  • All
  • 2018
  • ACMG
  • Case Study
  • Events/Conferences
  • Face2Gene
  • Genomics
  • Pharma
  • Pharma
  • Phenotyping
  • Rare Diseases
  • Scientific Abstracts
  • Talks
  • Technology
  • Uncategorized
  • Videos
  • Webinar

Dr. John Carey: Delineating Genetic Syndromes and Next-Generation Phenotyping

April 18, 2018

By Christen Baglaneas

2018,ACMG,Face2Gene,Phenotyping,Talks,Technology,Videos

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this link>

HISTORY

Since the 1960s, the field of medical genetics has been evolving rapidly with regard to phenotype delineation and analysis.

A disease phenotype requires a multi-faceted analysis. Besides defining the phenotype with diagnostic criteria, medical geneticists are also faced with the challenge of drawing lines along spectra of manifestations and within disease definitions, allowing for how symptoms may change over time.

To measure these variables, biochemical analysis, detailed histories, anthropometrics, standardized measures and medical imaging can be applied in concert. As next-generation sequencing evolves the way the medical field examines patients’ genomes, next-generation phenotyping integrates these changes into the analysis of human health, maximizing the impact of new sequencing technologies.

“We’ve actually entered a new golden era of phenotyping,” Dr. Carey said.

 

PHENOTYPIC DOMAINS

Dr. Carey noted there are three domains to measure disease: diagnostic criteria (a.k.a. definition of the phenotype), the spectrum of manifestations and complications, and natural history how the phenotype changes over time.

 

SYNDROME DELINEATION

Syndrome delineation has three distinct parts, as Dr. Carey reviewed in Charlotte, N.C. The first, the physical examination, involves observations and descriptions of the patients. Then there are two levels of syndrome genesis to consider: formal (e.g., a shortage or malformation of a critical enzyme) and causal (e.g., the genetic source of the formal genesis, such as a deletion or de novo mutation.)

 

SYNDROME GROUPS & HETEROGENEITY

The broad definition of syndrome classification is misleadingly simple: simply group patterns of anomalies, with at least one being morphologic, thought to be etiologically related. Of course, in practice, this is very different than in theory; groups of syndromes, variant forms, subtypes or related disorders can be hard to separate into discrete syndromes. Similar phenotypes can be caused by errors in different genes, or by multiple genes, and identical mutations can cause different phenotypes across patients.

 

 

“There are syndromes we know quite well that have 17 genes. There’s one gene that has 17 syndromes. Do we go with the gene or do we go with the phenotype?” Dr. Carey asked the audience.

 

THE AXIS MODEL

To solve these discrepancies, Dr. Carey proposed the use of the “axis model.” Axis I describes the clinical phenotype, Axis II describes the underlying molecular genetics, and Axis III describes non-genetic factors, like the environment.

“It’s never been adapted but I actually like it,” he said.

I would propose that even though you can’t [describe a syndrome in] 3 or 4 words, or less, Dr. Carey said of the sometimes wordy model. Despite its potential complication, its focus on phenotype keeps the naming mechanism patient-centered.

Watch the recording of the talk here.

 

More entries about 2018

Face2Gene
 

Extracting Features From Clinical Notes

DID YOU KNOW: By adding clinical features to your cases in Face2Gene, you increase the possible syndrome matches to 7,000+. NEW: Include features Read more

Face2Gene
 

2018 Year in Review

It was an exciting 2018 for FDNA, as we continued on our path to bring AI-based phenotyping technologies to clinicians, Read more

Events/Conferences
 

What to Do and See at ASHG 2018

San Diego, CA – The FDNA team is excited to be back at the American Society of Human Genetics (ASHG) Read more

2018
 

The Genomics Collaborative: How to Design the Future of Health—Together

  ThinkGenetic recently hosted a panel discussion among researchers involved in the Genomics Collaborative, an FDNA initiative connecting researchers, clinicians, Read more

ACMG
 

Dr. Christine Stanley: Face2Gene LABS at WuXi NextCODE: Phenotyping for Improved Variant Prioritization

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this link> Read more

ACMG
 

Dr. John Carey: Delineating Genetic Syndromes and Next-Generation Phenotyping

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this Read more

ACMG
 

Dr. Karen Gripp: Face2Gene RESEARCH for Deep Phenotyping of Novel Syndromes

Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this Read more

  • Contact Us
  • Privacy Policy
  • Terms of Use

Signup for News


* These fields are required.

© 2011-2021 FDNA INC. www.FDNA.com. All rights reserved.

Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician’s judgment or experience, nor should it be used to diagnose or treat medical conditions.